clinical trial · NCT04985604
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
MelanomaSolid TumorCRAF Gene AmplificationRAF1 Gene AmplificationBRAF Gene FusionBRAF FusionCRAF Gene FusionCRAF FusionTovorafenib
brief summary
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions or amplification.
started
Jul 15, 2021
primary completion
Jul 8, 2024
completion
Jul 8, 2024
last updated
Oct 2, 2025
official title
A Phase 2, Subprotocol of DAY101 Monotherapy for Patients With Recurrent, Progressive, or Refractory Solid Tumors With MAPK Pathway Aberrations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol